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Abstract 
The natriuretic peptides (NPs) are a family of related hormones that play important roles in 
the cardiovascular homeostasis, cell growth and neuroendocrine functions. Recently, they 
have emerged as potentially important clinical biomarkers in heart failure. The heart 
secretes two major natriuretic peptides: atrial natriuretic peptide (ANP) and brain 
natriuretic peptide (BNP), while C-type natriuretic peptide (CNP) is mainly secreted 
from the brain and blood vessels. The physiological effects of NPs are initiated by 
binding to natriuretic peptide receptors (NPRs), which are widely distributed in 
several organs. This review describes: the expression of natriuretic peptides in the 
cardiomyocytes differentiated from ES cells and their role in the cardiomyocyte 
development. We also describe the detailed distribution of NPRs in the central 
nervous system and their possible functions in various brain regions. 




The natriuretic peptides (NPs) are a family 
of three peptide hormones: atrial 
natriuretic peptide (ANP), brain natriuretic 
peptide (BNP), and C-type natriuretic 
peptide (CNP) [1-4]. NPs are released into 
the circulation from cardiac cells to act as 
hormones in the control of fluid volume 
homeostasis and blood pressure by 
causing natriuresis, diuresis, 
vasorelaxation and inhibition of the renin–
angiotensin–aldosterone system [5].  In 
addition, cell-based studies have shown 
that ANP and BNP exhibit important 
autocrine and paracrine functions such as 
modulating myocyte growth, apoptosis 
and proliferation in smooth muscle cells 
[6] and cardiac myocytes [7], and suppress 
cardiac fibroblast proliferation [8] and 
extracellular matrix secretion [8-9]. Their 
local production or presence in various 
extracardiac tissues suggests additional 
activities, including roles as neuropeptides 
[10-21]. The physiological effects of 
natriuretic peptides are initiated by 
binding to cell surface receptors. These 
include natriuretic peptide receptor type A 
(NPR-A), which is sensitive to ANP and 
BNP [22], natriuretic peptide receptor type 
B (NPR-B), which is highly specific for 
CNP [23], and natriuretic peptide receptor 
type C (NPR-C), which may comprise up 
to 95% of the total NPR population [24] 
and is known to bind all the natriuretic 
peptides with similar affinity [5].  The 
hormone binding to NPR-A and NPR-B 
results in activation of guanylyl cyclase 
and production of cGMP, which is 
believed to be the second messenger for a 
number of biological responses associated 
with natriuretic peptides [22, 25, 26].The 
NPR-C has been involved in peptide 
clearance, removing natriuretic peptides 
[27], and in the mediation of natriuretic 
peptide-induced inhibition of cyclic 
adenosine monophosphate (cAMP) 
synthesis, and activation of phospholipase 
C without affecting cGMP levels [28-29].  
In this review, we focus on the ability of 
ES cells to differentiate into functional 
cardiomyocytes, which have the ability to 
produce natriuretic peptides in vitro. In 
addition, we discuss the distribution of 
NPRs in the brain and their possible 
functions in various types of neurons. 
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Figure 1. Schematic showing the types of natriuretic peptides and their receptors. 
             
Figure 2. Expression of ANP and BNP in ES cell-derived cardiomyocytes. Note, the perinuclear 
localization of ANP and BNP. Bar = 50 µm.
Natriuretic peptides in ES cell-derived 
cardiomyocytes 
The heart is the first functioning organ in 
the embryo and any impairment of its 
function leads to early lethality [30]. 
Cardiomyocytes do not regenerate after 
birth, and they respond to mitotic signals 
by increasing in the size (hypertrophy) 
rather than by cell division (hyperplasia) 
[31]. Recently, embryonic stem (ES) cells 
and adult cardiac stem cells have been 
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proposed as transplantable cell candidates 
that would avoid the problems caused by 
other types [32-35]. Although, adult 
cardiac stem cells are capable of 
differentiating into cardiomyocytes [34-
35], and to proliferate to some extent in 
vitro, the rarity of cardiac-specific stem 
cells makes them difficult to isolate from 
biopsy specimens and poses a problem for 
their future clinical application [36]. On 
the other hand, transplanted ES cell-
derived cardiomyocytes have been shown 
to survive, proliferate and connect with 
host myocardium [37]. Therefore, the 
generation of functional cardiomyocytes 
from ES cells has potential applications 
including myocardial repair through cell 
transplantation. One of the important 
functions of cardiomyocytes is their 
production of natriuretic peptides, which 
secreted into circulation to perform several 
functions in the body [5] (Fig. 2). 
Previously, we could differentiate monkey 
ES cells into functional cardiomyocytes 
that can produce natriuretic peptides [38, 
Fig. 2]. Furthermore, it has been reported 
that myocardial tissue produced after 
ectopic transplantation of mice ES cell-
derived cardiomyocytes showed 
natriuretic peptides expression in vivo [39]. 
These data suggest that natriuretic 
peptides can be expressed after 
transplantation of ES cell-derived 
cardiomyocytes to perform its important in 
vivo function in maintaining the 
cardiovascular homeostasis [6]. 
The presence of natriuretic peptides at 
early stages of ES cell-derived 
cardiomyocyte development suggests 
the involvement of natriuretic peptides 
in cardiomyocyte development. In vivo, 
ANP and BNP levels in fetal ventricles 
have been reported to be greater than in 
the adult ventricle [41-42]. It is known that 
natriuretic peptide receptors are expressed 
in the heart itself [24]. It has been reported 
that ANP increases the proliferative 
activity, expression of contractile proteins 
and DNA synthesis of cultured chick 
embryo cardiomyocytes through receptor-
mediated pathway [43]. Other studies 
using a locker of NPR-A and NPR-B 
showed inhibitory effect of endogenous 
natriuretic peptides on cardiomyocytes 
hypertrophy [7]. More recent data 
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suggested that ANP might antagonize 
cardiomyocyte hypertrophy-promoting 
effects of vasoactive peptides and / or 
growth promoting factors [44]. These 
studies suggest that ANP has mitogenic 
action on embryonic cardiomyocytes and 
inhibitory  function on hypertrophy of 
adult cardiomyocytes. 
Interestingly, mice with targeted 
deletion of BNP exhibit a different 
phenotype than ANP-deficient mice. Mice 
without BNP do not have hypertension or 
cardiac hypertrophy; instead they show 
focal ventricular fibrotic lesions with a 
remarkable increase in factors, which 
implicated in the generation and 
progression of ventricular fibrosis [45]. 
Therefore, the BNP may have a role as a 
local, paracrine antifibrotic factor within 
the heart. These findings suggest 
complementary roles of ANP and BNP in 
the regulation of myocardial structure. The 
precise reason remains unknown.  
However, a possibility is speculated that 
there may be a separate unknown receptor 
for BNP in cardiac fibroblasts [45]. Thus, 
the in vitro expression of natriuretic 
peptides observed in the ES cell– derived 
cardiomyocytes, together with their 
elevated levels seen in vivo during normal 
heart formation [46], suggest a paracrine 
and/or autocrine function for natriuretic 
peptides during in vivo embryonic cardiac 
development as well as in vitro ES cell–
derived cardiomyocyte development. 
These observations suggest that cardiac 
natriuretic peptides may play a role in the 
regulation of cardiomyocyte development 
in vivo and in vitro. 
Cardiac gene expression of both ANP and 
BNP is increased in animal models of 
myocardial infarction [47], heart failure 
[48] and hypertrophy [49]. Therefore, the 
appearance of increased ANP expression 
in adult ventricles has become a marker 
for the embryonic gene program during 
the development of ventricular 
hypertrophy [50]. Overexpression of the 
NPR-A gene in the heart reduced cardiac 
myocyte size. Coincident with the 
reduction in myocyte size, ANP was 
reduced significantly at both mRNA and 
peptide levels by the overexpression of 
NPR-A. Thus, cardiac overexpression of 
NPR-A reduced cardiomyocyte size and 
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ventricular ANP expression, suggesting a 
role of NPR-A/cGMP signaling pathway 
in the regulation of cardiac myocyte 
hypertrophy and ANP mRNA expression 
[51].  
              
Figure 3. Proposed model for transplantation of ES cell-derived functional cardiomyocytes into 
infracted heart. Pluripotent ES cells differentiate into functional cardiomyocytes in vitro then 
transplanted into infracted region. Another method, undifferentiated ES cells are directly transplanted 
into infracted regions, and then they differentiate into functional cardiomycoytes in vivo.  As a result of 
successful transplantation, cardiac functions are improved leading to secretion of natriuretic peptides 
into the circulation to regulate cardiovascular homeostasis. 
The data presented here suggest that the 
production of fully functional 
cardiomyocytes, which can produce NP 
hormones from ES cell is important for 
proper development of cardiomyocytes 
and for their application in cell therapy 
(Fig. 3). 
 
Natriuretic peptide receptors 
(NPRs) in the brain 
 We have reported that NPR-A (Fig. 4A) 
and NPR-C (Fig. 4B) were localized to 
neurons in specific nuclei of the brain 
stem [20-21].  In addition to our reports, 
the NPRs were found in various regions in 
the CNS (Table 1), and in several species 
including, rat, guinea pig, human, monkey, 
and cat [13-16]. Neuronal NPR-A mRNA 
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was observed in the mitral cell layer of the 
olfactory bulb, media; habenula, area 
postrema, and glia cells [14]. In rat, NPR-
B mRNA is expressed in the limbic cortex, 
neocortex, olfactory bulb, hippocampus, 
amygdala, preoptic-hypothalamic 
neuroendocrine circuits, ventral tegmental 
area, substantia nigra, in motor nuclei of 
cranial nerves, in brainstem nuclei 
controlling autonomic function, and 
pituitary gland (14-15, 52). NPR-C mRNA 
is expressed in many rat brain regions, 
including the frontal and retrosplenial 
granular cortices, medial preoptic nucleus, 
ventral cochlear nucleus, choroid plexus, 
deep layers of the neocortex and limbic 
cortex, posterior cortical amygdala, ventral 
subiculum, amygdalohippocampal area, 
and dentate gyrus in the rat brain [13]. In 
monkey brain, in situ hybridization 
analysis has demonstrated that NPR-C 
mRNA is localized to neurons in cerebral 
cortex and cerebellum [53], suggesting a 
species difference in cerebellar NPR-C 
expression.  Moreover, in the forebrain, 
NPR-C shows a lack of overlap with the 
distribution of NPR-A and NPR-B 
mRNAs [13, 15].  
Although several studies showed the 
expression of NPR mRNAs in the CNS 
[17-18, 54-55], a few studies demonstrated 
their protein expression in the CNS [20-21, 
52], NPR-A protein was observed in 
several regions, including the oculomotor 
nucleus, red nucleus, locus coeruleus, 
parabrachial nucleus, the principal 
trigeminal sensory nucleus, dorsal motor 
nucleus of the vagus, the hypoglossal 
nucleus, the gracile nucleus, the cuneate 
nucleus, the nucleus ambiguus, the 
reticular formation, the lateral reticular 
nucleus, and the inferior olivary nucleus. 
In rat, NPR-B immunoreactivity were 
found to be localized in the ventral 
tegmental area, substantia nigra, caudate-
putamen, nucleus accumbens, frontal 
cortex, hippocampus, cortex, cerebellum 
[52]. NPR-C protein was observed in 
several regions of the brainstem, including 
the periaqueductal gray, red nucleus, locus 
coeruleus, dorsal tegmental nucleus, 
nucleus of the trapezoid body, 
ventrolateral pons including A5, cranial 
motor nuclei, dorsal motor nucleus of the 
vagus, nucleus ambiguus, and 
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ventrolateral medulla including A1 and 
inferior olivary nucleus [21].  
The distribution of natriuretic peptide 
receptor immunoreactivities in the 
brainstem showed a close anatomical 
relationship among them. The presence of 
both guanylyl cyclase receptors (NPR-A 
and NPR-B) in the same regions suggests 
the action of ANP, BNP and CNP in these 
regions, which indicate similar functions 
of natriuretic peptide hormones in the 
same regions. On the other hand, the 
presence of NPR-B and NPR-C in the 
same regions may suggest a role of NPR-
C in limiting the CNP in these areas for 
local action, or a synergetic role of NPR-B 
and NPR-C in modulating CNP functions. 
In the retina, NPR-A and NPR-B are also 
localized to neuronal elements, including 
bipolar cells and amacrine cells, in 
addition to the two plexiform layers and 
Müller glial cells [55, 56]. Double labeling 
experiments in rat retina have revealed 
expression of NPR-A and NPR-B in 
dopaminergic amacrine cells, whereas 
cholinergic amacrince cells express NPR-
B [56], suggesting that natriuretic peptides 
have different regulatory systems in 
dopaminergic and cholinergic amacrine 
cells in rat retina. 
Several studies demonstrated that NPRs 
are localized to glial cells in several 
regions of the brain [58-62]. It was 
reported that NPR-A and NPR-B are 
found only in non-neuronal elements in 
both mixed cultures of the CNS and brain 
slices. Also, incubation of astrocytes in 
culture with ANP increases intracellular 
cGMP levels [58]. NPR-A is 
predominantly expressed in SHR 
(spontaneously hypertensive rat) and 
WKY (Wistar-Kyoto, normotensive) rat 
astrocyte glial cultures [63]. NPR-B 
mRNA has been demonstrated in astrocyte 
cultures [64]. However, in situ 
hybridization study on rat brain didn’t 
detect NPR-B glial signal [14]. Cultured 
astrocytes also express abundant NPR-C 
[63]. In bullfrog retinal Müller glial cells, 
receptor of ANP is also functionally 
expressed [66]. Taken together, these 
findings suggest that natriuretic peptides 
have functions in glial cells.  
 9
           
Figure 4. Examples of the localization of NPR-A and NPR-C immunoreactivities in the neurons of the 
brainstem. Bar = 50 µm. 
 
Possible function of NPRs in the 
CNS 
The important role of the ANP/NPR-A 
system in the physiological regulation of 
arterial blood pressure and volume has 
been emphasized in various genetic mouse 
models. Targeted deletion of the peptide 
(ANP-/-) or its receptor (GC-A-/-), leads to 
severe, chronic arterial hypertension, 
cardiac hypertrophy, and sudden death 
[67-69]. In contrast, overexpression of 
ANP or NPR-A elicits a "dose-dependent" 
fall in arterial blood pressure [71]. ANP 
and NPR-A transcripts were found to be 
up-regulated for prolonged periods in rat 
cerebral cortex following acute cortical 
spreading depression [70]. It is of interest 
that NPR-C appears to mediate the 
mitogenic action of natriuretic peptides in 
Schwann cells [16, 29, 72]. Mice lacking 
the NPR-C gene Npr3 show reduced blood 
pressure and skeletal deformities 
associated with a considerable increase in 
bone turnover [73]. In addition, the 
elimination of NPR-C by antisense has 
also been reported to attenuate inhibitory 
effects of CNP on evoked neurotransmitter 
efflux in PC12 cells [18]. The anti-
proliferative actions of ANP on astrocytes 
are reported to be mediated by NPR-C 
[54]. In rat hypothalamus, CNP inhibits 
the calcium current in magnocellular 
neurosecretory cells through its effect on 
NPR-C [57]. Natriuretic peptides inhibit 
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the stimulated proliferation of astrocytes 
via actions at NPR-C [54], and enhance 
the survival of PC12 and embryonic basal 
forebrain cells [74].
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Table 1. Distribution of NPRs in the brain. 
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In the monkey brainstem, NPR-A  
immunoreactivity overlaps with 
cholinergic neurons in the parabrachial 
nucleus, the dorsal motor nucleus of the 
vagus, the hypoglossal nucleus, and the 
nucleus ambiguus [20]. Also, a large 
proportion of cholinergic neurons in the 
cranial motor nuclei and dorsal tegmental 
nucleus express NPR-C [21]. Furthermore, 
NPR-B has been detected in brainstem 
motor nuclei [14], suggesting its presence 
in cholinergic neurons. These data suggest 
a possible function of all natriuretic 
peptides in cholinergic neurons. 
Previous reports have shown the role of 
central cholinergic pathways in the 
secretion of hormones involved in fluid 
and electrolyte balance [75]. For example, 
cholinergic stimulation of the 
anteroventral third ventricle induces an 
increase in plasma ANP as well as a 
marked elevation of peptide content in the 
medial basal hypothalamus, neuro and 
adenohypophysis [75]. Furthermore, 
cholinergic neurons in the dorsal motor 
nucleus of the vagus are preganglionic 
parasympathetic neurons that send axons 
to visceral organs such as the heart and 
kidney. Also, some of the cholinergic 
neurons in the nucleus ambiguus project to 
the heart, and thereby play an important 
role in cardiac regulation of arterial blood 
pressure [76, 77]. Microinjection of ANP 
into the nucleus ambiguus causes a 
marked bradycardia [78]. These findings, 
along with the previous results showing 
the presence of NPRs in cholinergic 
neurons in the dorsal motor nucleus of the 
vagus and nucleus ambiguus [20-21], 
suggest the involvement of natriuretic 
peptides in cardiovascular control through 
activation of cholinergic neurons 
expressing natriuretic peptide receptors. 
A previous study has also demonstrated 
that natriuretic peptides and their receptors 
are expressed in the eye [56, 79-80], and 
recently all natriuretic peptide hormones 
and NPR-B were detected in cholinergic 
retinal amacrine cells [56, 81]. These 
observations suggest that natriuretic 
peptides also play a role in regulating eye 
functions through cholinergic neurons in 
the brainstem. 
 
NPRs were detected in regions contain 
catecholaminergic neurons. NPR-A was 
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seen in the locus coeruleus which did not 
overlap with TH-positive neurons [20]. 
However, NPR-C immunoreactivity was 
observed in several catecholaminergic cell 
groups, including the A6, A5, A1, C3 and 
C1 cell groups. Furthermore, it has been 
reported that some of these nuclei contain 
NPR-B mRNA [14].  Since NPR-B is a 
specific receptor for CNP, these data 
suggest that NPR-C may bind CNP, but 
not ANP or BNP, in catecholaminergic 
neurons of these regions.  
The interactions of natriuretic peptides 
with catecholaminergic neurons have been 
well documented in previous studies. 
Locus coeruleus neurons have a presser 
function. For example, the selective 
stimulation of noradrenergic cell bodies in 
the locus coeruleus elicits decreases in 
blood pressure, renal sympathetic activity 
and heart rate [82-84]. Furthermore, the 
ventrolateral medulla contains 
catecholaminergic neurons which are 
known to be important in cardiovascular 
control. Natriuretic peptides induce 
significant increases in TH mRNA 
through a cGMP-dependent 
phosphodiesterase pathway and protein 
kinase G-dependent mechanisms, which in 
turn results in stimulation of 
catecholamine synthesis in PC12 cells [85]. 
Furthermore, in spontaneously 
hypertensive rats, local microperfusion of 
ANP or an NPR-C agonist into the 
anterior hypothalamus reduces the release 
of noradrenalin from nerve terminals, an 
effect accompanied by an increase in 
arterial blood pressure [86]. All these 
results suggest that natriuretic peptides 
regulate cardiovascular function, partly by 
modulating catecholaminergic neurons. 
In addition to the established roles for 
natriuretic peptides in regulating 
neuroendocrine and cardiovascular 
functions, and fluid-electrolyte balance [5], 
NPs and NPRs were found in regions not 
related to the mentioned functions. A 
previous study showed that CNP inhibits 
dopamine release by stimulation of NPR-
B receptors and the increase in 
intracellular GMP concentration [87]. In 
addition, CNP can regulate cocaine-
induced dopamine release and expression 
of immediate early genes in brain neurons 
[52].  Interestingly, CNP has been found 
to improve learning and consolidation of 
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learning in a passive avoidance paradigm 
and dopamine has been shown to be one of 
the mediating neurotransmitters in the 
effect of CNP on learning [88]. Recent 
reports have shown that only the 
natriuretic peptides binding to NPR-C 
inhibit adrenergic neurotransmitter efflux 
[17-18]. Moreover, natriuretic peptides 
and their receptors, NPR-A and NPR-B, 
have been found in dopaminergic retinal 
amacrine cells [56, 81]. Taken together, 
these results suggest that CNP may 
regulate the activity of catecholaminergic 
neurons in several regions of the rat 
brainstem through binding to NPR-C. The 
functional significance of NPRs in several 
regions in the brain remains to be 
elucidated. 
Perspectives 
Genetic models and pharamcological 
studies have shown that the NPs play 
important roles in the regulation of 
cardiovascular homeostasis, skeletal 
growth. In addition, the NP signaling 
system may be important for 
cardiomyocyte development as shown by 
their expression at early stages of heart 
development and in ES cell-derived 
cardiomycoytes, and their expression after 
transplantation is important to maintain 
cardiac functions. On the other hand, 
NPRs are widely distributed throughout 
the brain in regions related to 
cardiovascular control and in other regions 
related to other functions, suggesting the 
involvement of NP system in broad range 
of functions in the brain. A better 
understanding of the functions and 
regulation of NP system may provide an 
opportunity to clarify their roles during 
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